文献速递泌尿男性生殖肿瘤

大肠埃希菌特异性产生CXCL13的滤泡辅助性T细胞与肌层浸润性膀胱癌新辅助PD-1阻断治疗的临床疗效相关

Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
PubMed 文献 · Cancer Discov · 2022-01-01

研究对肌层浸润性膀胱癌患者的肿瘤和血液样本进行分析,发现滤泡辅助性CD4+ T细胞(TFH)是与帕博利珠单抗疗效及无进展生存相关的最佳治疗靶点之一。TFH与基线肿瘤CD8及PD-L1表达、帕博利珠单抗诱导的第三级淋巴结构相关。血浆CXCL13仅见于应答者,组织内IgG4+CD38+ TFH与临床获益相关,针对尿路上皮侵袭性大肠埃希菌的TFH和IgG在三个独立队列中决定帕博利珠单抗的临床应答。

要点

  • TFH是与帕博利珠单抗疗效及无进展生存相关的最佳治疗靶点之一。
  • 血浆CXCL13仅见于应答者,组织IgG4+CD38+ TFH与临床获益相关。
  • 针对尿路上皮侵袭性大肠埃希菌的TFH和IgG在三个独立队列中决定帕博利珠单抗应答。

核心结论

  • 在肌层浸润性膀胱癌新辅助帕博利珠单抗治疗中,大肠埃希菌特异性产生CXCL13的TFH和IgG构成预测临床获益的生物标志物。
  • 针对大肠埃希菌的这类免疫应答除作为生物标志物外,可能被用于未来治疗策略。

研究设计与样本

  • 研究对接受新辅助帕博利珠单抗治疗的肌层浸润性膀胱癌患者的肿瘤和血液样本进行特征分析。
  • 关键发现分别在三个独立队列中进行了验证。

主要发现

  • TFH与基线肿瘤CD8及PD-L1表达相关,并与帕博利珠单抗诱导的第三级淋巴结构相关。
  • 血液中央记忆TFH聚集于肿瘤并产生CXCL13,该趋化因子仅见于应答者血浆。
  • 驻留膀胱组织的IgG4+CD38+ TFH与临床获益相关。
  • 针对尿路上皮侵袭性大肠埃希菌的TFH和IgG在三个独立队列中决定帕博利珠单抗的临床应答。

临床怎么用

  • 肿瘤感染与免疫检查点阻断免疫调节成功之间的联系应在前瞻性、更大规模研究中评估。

局限性

  • 肿瘤感染与免疫检查点阻断免疫调节成功之间的联系应在前瞻性、更大规模研究中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. SIGNIFICANCE: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Goubet AG, Lordello L, Alves Costa Silva C, et al. Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discov. 2022. PMID: 35929803. doi:10.1158/2159-8290.CD-22-0201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。